Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-04-2023 | Adenovirus | Case report

Multiple drugs

Infections and off-label use: 3 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Shirai T, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clinical and Experimental Rheumatology 41: 291-300, No. 2, Feb 2023. Available from: URL: http://doi.org/10.55563/clinexprheumatol/8kulbf Shirai T, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clinical and Experimental Rheumatology 41: 291-300, No. 2, Feb 2023. Available from: URL: http://​doi.​org/​10.​55563/​clinexprheumatol​/​8kulbf
Metadata
Title
Multiple drugs
Infections and off-label use: 3 case reports
Publication date
01-04-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-37700-4

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Epoprostenol

Case report

Ajmaline

Case report

Multiple drugs

Case report

Blinatumomab

Case report

Orelabrutinib